Mitchell Shirvan

Executive

Silexion Therapeutics CorpFoamix Pharmaceuticals Ltd.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€27k

Latest filing published 30 Mar 2026 for Silexion Therapeutics Corp, €27k.

Filing timeline

BuySale

Mitchell Shirvan

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Mitchell Shirvan: trading record in brief

Mitchell Shirvan discloses dealings in 2 companies, chiefly Foamix Pharmaceuticals Ltd. and Silexion Therapeutics Corp. Over a trading history stretching from 1 January 2018 to 26 March 2026, the count stands at 5 filings.

Sales make up the whole of the open-market record (1 sale, €27k). The rest of the record consists of 2 share grants and 2 option exercises. Since January 2026: no purchases and 1 sale on the market.

Most recently, on 30 March 2026, the filings show an open-market sale worth €27k in Silexion Therapeutics Corp. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.